Conclusion
Based upon our experience, LVAD implantation in sickle-cell trait is
safe and offers a remarkable improvement in patient outcomes. In spite
of the limited numbers of patients enrolled in this case-series, the
findings suggest that LVAD implantation can be successfully performed in
patients with SCD trait by applying meticulous pre-operative,
intra-operative, anesthetic, and post-operative management protocols.
However, the literature on the specific evaluation and management of
these patients remains limited and further studies are still needed to
provide more evidences on this practice.